Cargando…
A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer
SIMPLE SUMMARY: Blockade of the immunosuppressive CD73/ADO immune checkpoint has been suggested as a promising alternate immunotherapeutic approach for refractory ovarian cancer (OC). Despite promising preclinical results, midterm clinical trial reports indicate that the efficacy of the CD73-blockin...
Autores principales: | Ploeg, Emily Maria, Britsch, Isabel, van Wijngaarden, Anne Paulien, Ke, Xiurong, Hendriks, Mark Alexander Johannes Martinus, Samplonius, Douwe Freerk, Helfrich, Wijnand |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378099/ https://www.ncbi.nlm.nih.gov/pubmed/37509310 http://dx.doi.org/10.3390/cancers15143651 |
Ejemplares similares
-
Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR
por: Ploeg, Emily Maria, et al.
Publicado: (2023) -
Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα “don’t eat me” immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation
por: Hendriks, Mark A. J. M., et al.
Publicado: (2020) -
Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selective eliminate carcinoma cells
por: Britsch, Isabel, et al.
Publicado: (2023) -
The detection of EpCAM(+) and EpCAM(–) circulating tumor cells
por: Wit, Sanne de, et al.
Publicado: (2015) -
Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas
por: Fong, Dominic, et al.
Publicado: (2014)